BSO-07

• UNSPSC Description:

  BSO-07 is a ROS/JNK activator with significant anticancer effects, having an IC50 value of 24.81 μM against human breast cancer (BC) cells. BSO-07 induces apoptosis (Apoptosis) and paraptosis by activating JNK and increasing ROS levels, including enhancing the expression of apoptosis-associated proteins such as PARP, Bax, phosphorylated p53, ATF4, and CHOP, while decreasing the levels of anti-apoptotic proteins like Bcl-2, Bcl-xL, and Survivin. BSO-07 holds promise for research in the field of breast cancer[1].

• Target Antigen:

  JNK; Reactive Oxygen Species

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;MAPK/ERK Pathway;Metabolic Enzyme/Protease;NF-κB

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bso-07.html

• Smiles:

  ClC1=CC=C(N2CCN(CC3=NO[C@](CCC4)([H])[C@]4([H])C3C5=CC=CC=C5)CC2)C(F)=C1

• Molecular Weight:

  427.94

• References & Citations:

  [1]Kim NY, et al. Oxazine drug-seed induces paraptosis and apoptosis through reactive oxygen species/JNK pathway in human breast cancer cells. Transl Oncol. 2024 Nov;49:102101.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported